Polyethylene Glycol 3350 + Movantik

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Opioid Induced Constipation

Conditions

Opioid Induced Constipation

Trial Timeline

Mar 2, 2017 → Aug 23, 2017

NCT ID

NCT03060512

About Polyethylene Glycol 3350 + Movantik

Polyethylene Glycol 3350 + Movantik is a approved stage product being developed by AstraZeneca for Opioid Induced Constipation. The current trial status is completed. This product is registered under clinical trial identifier NCT03060512. Target conditions include Opioid Induced Constipation.

What happened to similar drugs?

7 of 20 similar drugs in Opioid Induced Constipation were approved

Approved (7) Terminated (7) Active (7)

✅Naldemedine + PlaceboShionogiApproved

✅Naltrexone for extended-release injectable suspension + Oral naltrexoneAlkermesApproved

✅NaltrexoneAlkermesApproved

✅VIVITROL 380mgAlkermesApproved

✅methylnaltrexone + placeboBausch HealthApproved

✅Methylnaltrexone bromideBausch HealthApproved

✅Methylnaltrexone + PlaceboBausch HealthApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03060512	Approved	Completed	Mar 2, 2017	Aug 23, 2017	Opioid Induced Constipation

Competing Products

20 competing products in Opioid Induced Constipation

See all competitors

Product	Company	Stage	Hype Score
SUBLOCADE	Indivior PLC	Phase 3	29
SUBLOCADE	Indivior PLC	Phase 3	29
ASP8082 + morphine + Placebo	Astellas Pharma	Phase 1	29
ASP8062 + Placebo ASP8062 + buprenorphine/naloxone	Astellas Pharma	Phase 1	29
ASP8062 + Placebo ASP8062 + buprenorphine/naloxone	Astellas Pharma	Phase 2	27
Naldemedine + Placebo	Shionogi	Phase 3	40
Naldemedine + Placebo	Shionogi	Approved	50
Naldemedine	Shionogi	Phase 1/2	39
Naldemedine + Placebo	Shionogi	Phase 3	40
Placebo + Naldemedine	Shionogi	Phase 2	35
Naldemedine + Placebo	Shionogi	Phase 3	40
Naldemedine + Placebo	Shionogi	Phase 2	35
Naloxegol	Kyowa Kirin	Pre-clinical	26
naloxegol + non-PAMORA laxative	Kyowa Kirin	Pre-clinical	18
Naloxegol	Kyowa Kirin	Pre-clinical	26
Naloxegol	Kyowa Kirin	Pre-clinical	26
Brenipatide + Placebo + Buprenorphine	Eli Lilly	Phase 2	42
NKTR-118 + NKTR-118 + Placebo	AstraZeneca	Phase 3	32
Naloxegol + Naloxegol	AstraZeneca	Phase 1	29
NKTR-118 + Usual care	AstraZeneca	Phase 3	40